lightstone group net worth

The company successfully completed an IPO in 2021 (NASDAQ: CYT). Stacy currently serves as a non-executive Independent Director and member of the Compensation and Management Committee for Hill-Rom Holdings, Inc. (NYSE: HRC), Sonova Holding AG (VTX: SOON), and LivaNova, Inc. (NASDAQ: LIVN). New York, New York, United States 101-250 Debt Financing Private www.lightstonegroup.com/ 33,737 Highlights Investments 2 Total Funding Amount $644M Contacts 102 Employee Profiles 9 Investors 5 Similar Companies 8 Lightstone has invested directly in individual real estate assets and in real estate operating companies. She is from Canada. Lorem ipsum dolor sit, amet consectetur adipisicing elit. Mr. Lightstone Group Completes $2.3 Billion Disposition of Prime Outlets Client News 1988 Present June 1988 Founding of Lightstone Lightstone Group is a real-estate investment company that develops, manages and invests in all sectors of the real estate market. Lightstone Group is joining the ranks of real estate companies launching their own debt platforms. During his time at Split Rock, Jason was actively involved with the firms investment in Ardian (acquired by Medtronic), Cabochon Aesthetics (acquired by Ulthera), Atritech (acquired by Boston Scientific), Entellus Medical (acquired by Stryker), Evalve (acquired by Abbott), and Transcend Medical (acquired by Alcon). Lightstone team members have been involved in some of the largest venture-backed life science exits over the last decade including: Ardian, Acceleron, ALX Oncology, Calithera BioSciences, Claret Medical, Disarm Therapeutics, MicroVention, Nimbus, Plexxikon, Portola Pharmaceuticals, Promedior, Proteolix, Ra Pharma, Tizona Therapeutics, Twelve and Zeltiq. Last Update. Using a thesis-driven investment strategy, we focus on understanding key market sectors and seeking out disruptive technologies while building and nurturing relationships with key thought leaders. The show is well known for including interviews with various prominent Rabbis and Jewish community leaders and the lineup of personalities interviewed includes both Haredi and Modern Orthodox leaders. Willow is a medical device company commercializing a wearable breast pump that allows women to achieve their breastfeeding goals without pressing pause on their own lives. Lightstone Group REIT, P.O. [1] He developed an avid interest in property during his twenties and launched his real estate career after the purchase of a single building. He is a co-inventor on over 250 issued and pending U.S. patents. The company successfully completed an IPO in 2020 (NASDAQ: ALXO). He rapidly grew his portfolio in the 1990s, before diversifying his portfolio and moving into retail. By Mack Burke July 14, 2021 7:00 am. + $557 Million. Investors purchase shares within the REIT and receive a pro-rata share of income that is derived from the real estate. $6.5 Billion. View contacts for The Lightstone Group to access new leads and connect with decision-makers. Elcelyx Therapeutics is a biopharmaceutical company developing therapeutic agents based on the finding that modulation of the neuro-enteroendocrine system of the gut, including L-cells, amplifies the release of hormones such as those that play an important role in glucose regulation. Prior to LSV and ATV, Jean worked for BancBoston Ventures and led its life sciences investments in Neurometrix (NASDAQ:NURO), Ironwood Pharmaceuticals (NASDAQ: IRWD), NuGenesis Technologies (acquired by Waters) and Syntonix Pharmaceuticals (acquired by Biogen/Idec). Courtesy: Lightstone. Jason Lettmann is a General Partner of Lightstone Ventures and focuses on investments in the biopharmaceutical and medical technology sectors. Apreo Health is a development stage medical technology company that is developing innovative, globally applicable treatments for pulmonary disease. Cerevance is a biopharmaceutical company that is taking a novel approach to the discovery and development of therapeutics for CNS and psychiatric diseases utilizing its powerful NETSseq target discovery platform. Dr. Pons currently serves as the President and Chief Executive Officer of ALX Oncology. We are like-minded collaborators with a shared purpose: to integrate business and science into breakthrough companies that can change the lives of patients. [16] Following the success of Lightstone Value Plus, Lichtenstein launched a second non-traded REIT. in Biological Sciences from UC, Irvine, Volta Medical Secures 36M in Series B Funding to Support Adoption of its AI Software for Cardiac Ablation, New CFO Introduced, MaxCyte and Catamaran Bio sign strategic platform licence. . Find More Contacts for The Lightstone Group, Lightstone Group, Light Stone Group, Lightstone, Light Stone, Edit Lists Featuring This Company Section, CCI approves Lightstone Funds stake acquisition in PharmEasy, LGT Group spins out alternative investing, private banking and impact arms, Lightstone leads $50m Series B for Indian debt marketplace, Investors Active in United States (Top 10K). Sage Hospitality and The Lightstone Group are pleased to announce the signing of a franchise license agreement with Hilton Worldwide for a new DoubleTree by Hilton hotel location in Danvers, Mass. She has been recognized as one of the Top 100 Women in Business and is a frequent speaker on healthcare, innovation leadership and corporate culture. The success of a company is determined by its people, so we work closely with biotech and medtech founders to build teams with the experience and ambition necessary to achieve their goals. Lightstone has invested directly in individual real estate assets and in real estate operating companies. Prior to Independent Director work, Stacy served as the President of Covidiens $1.7B Vascular Therapies business. The company was incubated within The Foundry, the premier medical technology incubator. She was also the recipient of the National Science Scholarship from the Agency for Science, Technology, and Research (A*STAR) Singapore. These include the invention, identification and development of new technologies, the formation, financing, and staffing of over twenty new companies, and ongoing support of these new ventures as a board member. Consulting, working on projects across therapeutic areas, modalities and technologies, including pipeline optimization, go-to-market strategies, BD and M&A due diligence. Orexigen Therapeutics is a biopharmaceutical company developing therapies for the treatment of obesity. Contact information. Dr. Pons is an inventor of fremanezumab, which was approved by the FDA in 2018, as well as two other antibodies in late-stage clinical development and has advanced nine additional antibodies into human trials in multiple therapeutic areas. He is currently the Chief Financial and Operating Officer at Alchemab Therapeutics, an LSV portfolio company focused on developing novel antibody therapeutics generated from patients resilient to disease. (business & personal). The Lightstone Group LLC Lightstone Enterprises Ltd. Howard E. Friedman: Lightstone Value Plus REIT I, Inc. Terri Warren Reynolds: Lightstone Value Plus REIT V, Inc. Andreas K. Bremer: Lightstone Value Plus REIT V, Inc. Avidia is a biopharmaceutical company discovering and developing a new class of human therapeutic proteins called Avimer. Hanson is a Director of FIRE1, Contego, Reprieve Cardiovascular, Half Moon Medical, Tangible Science, Apreo Health, and Mavericks Endo. Since 2005, Lightstone has offered investors the opportunity to invest in a diversified portfolio of real estate through its various public non-traded REIT offerings. Our team works hands-on with founders to help establish a strategy that can transform their vision into commercially viable products. Cyteir Therapeutics is a biopharmaceutical company and a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases. In 2000, Lightstone began to invest in retail strips, and subsequently into investing in malls. Plain is Chairman of the Board of Trustees for the Naval Postgraduate School Foundation in Monterey, CA and serves on the board of the First Tee of Monterey County. Subsequently, recapitalized with Simon Property Group for $2.3b in December 2009, one of the firms most noteworthy successes, A public non-listed REIT, current AUM $509mm, 199-unit luxury rental property in Long Island City, Queens, 430-unit luxury rental property in Gowanus, Brooklyn, Awarded Development Project of the Year at ALIS (the American Lodging Investment Summit), Winner of Conde Nast Travelers 2020 Readers Choice Award Top 25 Hotels in NYC, 428-unit luxury rental property in Long Island City, Queens, Received Boutique Designs 2019 Goldkey Award for Best Midscale Hotel and Surface Magazines 2019 Travel Award for Best Micro-Hotel, Recognized as one of Business Insiders Top 20 NYC Hotels, Winner of Hospitality Designs Award for Best Select Service Hotel, 28-unit luxury condominium property in New York, NY, Bonds are rated A+ by Standard & Poors Maalot, 242-unit luxury condominium property in New York, NY, 202-room lifestyle hotel in South Beach, Miami, The acquisition from Hartman & Tyner increased Lightstones multifamily portfolio to over 23,000 units, Industrial and Retail Commercial Management, Investing and Developing Across The Country. Her journey has since spanned three continents and grew into various leadership roles such as national support manager and global marketing manager at Beckman Coulter in the United States; assistant professor and director of research at the American University of Beirut Medical Center; and finally to Ireland where she was a Site Lead at Becton Dickenson-Gencell and director of BDs Research Center Ireland. + $530 Million. Her representative investments include Acceleron Pharma (NASDAQ: XLRN), Calithera Biosciences (NASDAQ: CALA), Cyteir Therapeutics, Disarm Therapeutics (acquired by Eli Lilly), Flex Pharma (NASDAQ: FLKS), Five Prime Therapeutics (NASDAQ: FPRX), Gemini Therapeutics, Hypnion (acquired by Eli Lilly), Locanabio Therapeutics, Portola Pharmaceuticals (NASDAQ: PTLA), Proteolix (acquired by Onyx Pharmaceuticals), Tizona Therapetics (acquired by Gilead), Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ). The list is limited to the top 50 companies, all of which except Elevance Health have annual revenues exceeding US$140 billion. Jason also served as the interim CEO of Promedior and led the company through its sale to Roche in 2020. Box 219002 Kansas City, MO 64121-9002 Our experienced life science investors seek out visionary founders to translate novel scientific breakthroughs into clinically and commercially meaningful therapies. In 2020, Gilead Sciences (NASDAQ: GILD) purchased an option to acquire ~50% of the company. Principia Biopharma is a biopharmaceutical company developing novel compounds with enhanced sensitivity, high potency and longer duration of effect. Hanson is also a Managing Partner at The Foundry, LLC, a medical device company incubator and a preferred partner to LSV. Claret Medical is a medical device company developing innovative solutions for cerebral protection during structural heart and vascular interventions.